Good Samaritan To Purchase New Linear Accelerator

During Monday’s Board of Governor’s meeting, the Board voted to purchase a new linear accelerator to better serve the hospital’s cancer patients. The current linear accelerator, the Varian IX, purchased in 2006, increased treatment standards to accommodate Intensity Modulated Radiation Therapy (IMRT). This new standard of care provided Good Samaritan’s patients with a more uniform radiation dose while limiting to dose to surrounding tissue. The IX also brought the capability to ‘record and verify’ treatment parameters, along with the ability to accurately treat many different kinds of cancers and help ensure patients the highest quality of care.

In the last 12 years; however, linear accelerator treatment machines have become even more accurate and now capable of providing razor-sharp focus to eradicate the cancer target. Due to these technological advancements, Good Samaritan has decided to replace the IX with the Varian Edge™.

“The addition of the Varian Edge Radiosurgery System is an exciting opportunity for Good Samaritan to provide the most state of the art radiation treatments for our patients,” said Dr. Brian Gebhardt, Radiation Oncologist. “This system is designed to deliver highly conformal and accurate radiation doses to tumors in the brain with a technique called stereotactic radiosurgery as well as increase the speed and precision of treatments for other tumors throughout the body.” Oncology patients will also be able to make only one to three visits for radiation treatment opposed to the two-week course of whole brain irradiation.

“With the edition of the Varian Edge™, we will be able to offer our patients the most accurate linear accelerator on the market with sub-millimeter accuracy and less imaging exposure,” said Jane Russell, Director of Oncology. “I am excited for this addition to our Oncology Department.”

The purchase of the new linear accelerator, which will last Good Samaritan 10 years, will have a total cost of $2.9 million with a three-year return on investment.

Categories: News